Medicare Pays for Non-Opioid Tech: B. Braun Wins NOPAIN Act Approval

BETHLEHEM, Pa. – October 14, 2026 – For decades, the American healthcare system has grappled with a quiet, structural flaw: the financial architecture of outpatient surgery inherently favored the prescription of cheap, highly addictive opioids over innovative, opioid-sparing medical devices. Today, that architecture is undergoing a radical remodel.

B. Braun Medical Inc. announced today that the Centers for Medicare and Medicaid Services (CMS) has approved its Stimuplex Single-Shot Nerve Block Needles as qualifying non-opioid medical devices under the Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act. The approval, which is retroactively effective to April 30, 2026, allows outpatient surgical facilities to receive temporary, separate Medicare payments for these devices.

This development is far more than a routine regulatory nod for the Bethlehem, Pennsylvania-based medical technology manufacturer. It represents a critical intersection of federal policy, corporate strategy, and public health, illustrating how targeted reimbursement reforms can fundamentally alter the standard of care in surgical suites across the country.

Federal Policy as a Catalyst for Change

To understand the magnitude of the NOPAIN Act, one must look at the historical economics of Ambulatory Surgery Centers (ASCs) and Hospital Outpatient Departments (HOPDs). Historically, Medicare utilized a bundled payment system for these facilities. The facility received a single, flat fee for a surgical procedure, which was expected to cover all associated costs, including anesthesia and post-operative pain management.

This created a perverse financial disincentive. If an ASC administrator wanted to utilize an advanced, non-opioid pain management device—such as an elastomeric infusion pump or a specialized nerve block needle—the cost of that device ate directly into the facility's narrow profit margin for the procedure. Conversely, generic opioid pills cost pennies. Even when clinicians recognized the superior patient outcomes associated with non-opioid alternatives, the bundled payment model made widespread adoption economically punitive.

The NOPAIN Act, enacted in December 2022 and implemented for separate payments starting in 2025, dismantles this barrier. By mandating that CMS provide separate reimbursement for qualifying non-opioid treatments, the legislation effectively neutralizes the cost penalty.

"The inclusion of these B. Braun peripheral nerve block devices under the NOPAIN Act reflects the important role enabling technologies play in supporting multimodal, opioid-sparing pain management strategies," said Kristin Brown, Director of Pain Control Marketing at B. Braun Medical Inc.

Industry analysts note that this separate payment mechanism—often capped at approximately 18% of the HOPD fee schedule amount for the primary procedure—is forcing a rapid reassessment of purchasing contracts and clinical protocols. Facilities no longer have to choose between their financial health and the long-term health of their patients, paving the way for a surge in the adoption of regional anesthesia technologies.

Reshaping Ambulatory Surgery Through Regional Anesthesia

The clinical implications of this financial shift are profound. As surgical techniques have advanced, a vast array of procedures that once required multi-day hospital stays—from orthopedic joint replacements to complex hernia repairs—have migrated to the outpatient setting. This migration demands highly effective, fast-acting pain management that allows patients to recover safely at home.

B. Braun's Stimuplex needles are utilized in single-injection peripheral nerve block techniques. Rather than blanketing the central nervous system with systemic opioids—which carry risks of respiratory depression, severe nausea, prolonged recovery times, and long-term dependency—regional anesthesia targets the specific nerves serving the surgical site.

By blocking pain signals at the source, patients wake up from surgery with significantly reduced pain scores. This targeted approach not only accelerates the immediate post-operative recovery phase, allowing ASCs to improve patient throughput, but it also drastically reduces the need for take-home opioid prescriptions.

The CMS approval solidifies B. Braun's position in a rapidly evolving market. Citing 2024 data from iData Research, B. Braun already claims the mantle of U.S. market leader in regional anesthesia. However, the NOPAIN Act has ignited fierce competition. The list of qualifying non-opioid alternatives expanded from 11 in 2025 to 18 by early 2026. Competitors such as Avanos Medical, with its ON-Q and ambIT infusion pumps, and PAJUNK, with its echogenic nerve block needles, have also aggressively pursued and secured unique Healthcare Common Procedure Coding System (HCPCS) codes for separate payment.

This competitive rush benefits the entire healthcare ecosystem. As medtech companies vie for NOPAIN Act qualification, they are compelled to produce robust clinical and health economic data proving their devices genuinely reduce or replace opioid use, thereby elevating the overall quality of evidence-based practice.

The Ticking Clock: Medtech’s Race Against the 2027 Sunset

Despite the current momentum, a significant legislative hurdle looms on the horizon. The NOPAIN Act's separate payment provisions are temporary, currently scheduled to expire on December 31, 2027. This sunset clause has created a high-stakes race for both medical device manufacturers and healthcare advocacy groups.

For companies like B. Braun, the immediate strategic imperative is to drive rapid clinical adoption and gather real-world data demonstrating the cost-effectiveness and patient benefits of their technologies before the funding window closes. The goal is to prove to policymakers that the upfront cost of separate device reimbursement is vastly outweighed by the downstream savings of reduced opioid addiction, fewer hospital readmissions, and faster patient recovery.

Simultaneously, a massive lobbying effort is underway in Washington. Coalitions such as "Voices for Non-Opioid Choices" are actively campaigning to make the NOPAIN Act's provisions permanent. Lawmakers are also considering the proposed "Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act," which seeks to expand access further by addressing patient cost-sharing and utilization management within Medicare Part D plans.

The pressure on Congress is mounting. The NOPAIN Act mandates that the Secretary of Health and Human Services submit a comprehensive report detailing ongoing barriers to non-opioid access and recommending further improvements to Medicare coverage. While this report remains pending, its eventual release will likely serve as a critical flashpoint in the debate over reauthorization.

If Congress fails to act before the end of 2027, the healthcare system risks a sudden reversion to the bundled payment model, threatening to undo years of progress in the fight against the opioid epidemic. Until then, the medtech industry finds itself in a unique, time-bound era where federal policy and market forces are perfectly aligned, driving a transformation in pain management that prioritizes innovation and patient safety over the outdated economics of the past.